Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatmen…
$16.37+3.48%
报价 2026-11-09
市值
$879.8M
EV
$1.29B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -49.2%
$14.59$32.23
筛选结果
pipeline · 2026-11-09Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-09不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| AKTSAktis Oncology, Inc. | $879.8M | +3.5% | +109.6% | 87.2% | – | – | – | |
| PHARPharming Group N.V. | $931.4M | +7.1% | – | 86.5% | 72.0x | 20.1x | 24.5x | |
| ODTXOdyssey Therapeutics, Inc. | $920.3M | -0.4% | – | 0% | – | – | – | |
| MGTXMeiraGTx Holdings plc | $911.4M | +5.4% | +1275.9% | 91.6% | – | – | 144.5x | |
| GLUEMonte Rosa Therapeutics, Inc. | $902.6M | +0.1% | -46.7% | 95.3% | – | – | – | |
| SNDXSyndax Pharmaceuticals, Inc. | $859.8M | +0.1% | +87.0% | 96% | – | – | – | |
| ALMSAlumis Inc. Common Stock | $847.8M | +8.6% | -73.7% | 89.6% | – | – | – | |
| BBTXBambusa Therapeutics Inc. | $843M | +7.7% | – | – | – | – | – | |
| DNAGinkgo Bioworks Holdings, Inc. | $833M | +9.6% | -51.1% | 84.6% | – | – | – | |
| 同行中位数 | – | – | -46.7% | 89.6% | 72.0x | 20.1x | 84.5x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。